Literature DB >> 30302498

Opposing roles of eosinophils in cancer.

Sonja C S Simon1,2, Jochen Utikal1,2, Viktor Umansky3,4.   

Abstract

Eosinophils are a subset of granulocytes mostly known for their ability to combat parasites and induce allergy. Although they were described to be related to cancer more than 100 years ago, their role in tumors is still undefined. Recent observations revealed that they display regulatory functions towards other immune cell subsets in the tumor microenvironment or direct cytotoxic functions against tumor cells, leading to either antitumor or protumor effects. This paradoxical role of eosinophils was suggested to be dependent on the different factors in the TME. In addition, the clinical relevance of these cells has been recently addressed. In most cases, the accumulation of eosinophils both in the tumor tissue, called tumor-associated tissue eosinophilia, and in the peripheral blood were reported to be prognostic markers for a better outcome of cancer patients. In immunotherapy of cancer, particularly in therapy with immune checkpoint inhibitors, eosinophils were even shown to be a potential predictive marker for a beneficial clinical response. A better understanding of their role in cancer progression will help to establish them as prognostic and predictive markers and to design strategies for targeting eosinophils.

Entities:  

Keywords:  Cancer; Eosinophils; Immunotherapy; PIVAC 17; Prognostic marker

Mesh:

Substances:

Year:  2018        PMID: 30302498     DOI: 10.1007/s00262-018-2255-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  32 in total

Review 1.  Deciphering the role of eosinophils in solid organ transplantation.

Authors:  Oscar Okwudiri Onyema; Yizhan Guo; Atsushi Hata; Daniel Kreisel; Andrew E Gelman; Elizabeth A Jacobsen; Alexander Sasha Krupnick
Journal:  Am J Transplant       Date:  2019-11-18       Impact factor: 8.086

2.  Absolute Increase in the Number and Proportion of Peripheral Eosinophils Associated With Immune Checkpoint Inhibitor Treatment in Non-small Cell Lung Cancer Patients.

Authors:  Hajime Osawa; Toshihiro Shiozawa; Shinichiro Okauchi; Yuika Sasatani; Gen Ohara; Shinya Sato; Kunihiko Miyazaki; Takahide Kodama; Katsunori Kagohashi; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Cancer Diagn Progn       Date:  2021-11-03

Review 3.  Solving the Conundrum of Eosinophils in Alloimmunity.

Authors:  Cherie Alissa Lynch; Yizhan Guo; Zhongcheng Mei; Daniel Kreisel; Andrew E Gelman; Elizabeth A Jacobsen; Alexander Sasha Krupnick
Journal:  Transplantation       Date:  2021-12-27       Impact factor: 5.385

Review 4.  Proteomics and its applications in breast cancer.

Authors:  Anca-Narcisa Neagu; Danielle Whitham; Emma Buonanno; Avalon Jenkins; Teodora Alexa-Stratulat; Bogdan Ionel Tamba; Costel C Darie
Journal:  Am J Cancer Res       Date:  2021-09-15       Impact factor: 5.942

Review 5.  Contributions of Eosinophils to Human Health and Disease.

Authors:  Amy D Klion; Steven J Ackerman; Bruce S Bochner
Journal:  Annu Rev Pathol       Date:  2020-01-24       Impact factor: 23.472

Review 6.  Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.

Authors:  Karmela Kim Chan; Cynthia Magro; Alexander Shoushtari; Charles Rudin; Veronica Rotemberg; Anthony Rossi; Cecilia Lezcano; John Carrino; David Fernandez; Michael A Postow; Arlyn Apollo; Mario E Lacouture; Anne R Bass
Journal:  Oncologist       Date:  2019-10-15

Review 7.  Lessons learned from targeting eosinophils in human disease.

Authors:  Fei Li Kuang; Bruce S Bochner
Journal:  Semin Immunopathol       Date:  2021-04-23       Impact factor: 11.759

Review 8.  Tuning the Tumor Myeloid Microenvironment to Fight Cancer.

Authors:  Nadine S Jahchan; Adriana M Mujal; Joshua L Pollack; Mikhail Binnewies; Venkataraman Sriram; Leonard Reyno; Matthew F Krummel
Journal:  Front Immunol       Date:  2019-07-25       Impact factor: 7.561

9.  Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database.

Authors:  Quentin Scanvion; Johana Béné; Sophie Gautier; Aurélie Grandvuillemin; Christine Le Beller; Chouki Chenaf; Nicolas Etienne; Solenn Brousseau; Alexis B Cortot; Laurent Mortier; Delphine Staumont-Sallé; Franck Morschhauser; Alexandra Forestier; Matthieu Groh; David Launay; Eric Hachulla; Myriam Labalette; Jean-Emmanuel Kahn; Guillaume Lefèvre
Journal:  Oncoimmunology       Date:  2020-04-07       Impact factor: 8.110

10.  Peripheral blood eosinophilia may be a prognostic biomarker in non-small cell lung cancer patients treated with immunotherapy.

Authors:  Adelaide Alves; Margarida Dias; Sérgio Campainha; Ana Barroso
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.